Search Results

You are looking at 71 - 80 of 1,743 items for :

  • "chemotherapy" x
Clear All
Full access

Mary F. Mulcahy and Al B. Benson III

single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study . Ann Oncol 1998 ; 9 : 105 – 108 . 13 Becouarn Y Ychou M Ducreux M . Phase II trial of oxaliplatin as first-line chemotherapy in metastatic

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt and Michael K. Wong

Web site at www.nccn.org .) These guidelines are also available on the Internet. For the latest update, please visit www.nccn.org . References 1 Dale DC McCarter GC Crawford J . Myelotoxicity and dose intensity of chemotherapy

Full access

Anat Gafter-Gvili, David P. Steensma and Michael Auerbach

More than a decade has passed since Auerbach et al 1 presented the first study demonstrating synergy of intravenous (IV) iron with erythropoiesis-stimulating agents (ESAs) for correcting anemia in patients receiving chemotherapy for malignant

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King and Sasha Lupichuk

Background Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. Landmark meta-analyses by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in

Full access

Jeffrey Crawford and George M. Rodgers

Chemotherapy-induced neutropenia is hazardous for 2 reasons: it produces febrile neutropenia (FN), which may result in life-threatening infections and prolonged hospitalizations, and it can necessitate chemotherapy dose reductions and delays

Full access

Rosalyn A. Juergens and Julie R. Brahmer

CP . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med 2002 ; 346 : 92 – 98 . 4. Sandler AB Gray R Brahmer J . Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or

Full access

Data adapted from Bergstrom et al. 1 Data based on reporting from 750 community oncology practices in the United States to McKesson Specialty Care Solutions. Adjuvant chemotherapy for breast cancer has evolved over several decades

Full access

Matthew D. Galsky, Harry W. Herr and Dean F. Bajorin

value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer—Genitourinary Group . J Urol 1992 ; 147 : 606 – 608 . 11

Full access

Emil Lou, Donna D'Souza and Andrew C. Nelson

carcinoembryonic antigen (CEA) biomarker while on combination chemotherapy (FOLFIRI with bevacizumab), bevacizumab was discontinued in favor of initiating an EGFR inhibitor (panitumumab) while continuing the FOLFIRI backbone. This alteration to her treatment

Full access

Peyman Haghighat and Tanios Bekaii-Saab

chemotherapy plus best supportive care with best supportive care in advanced gastric cancer . Ann Oncol 1997 ; 8 : 163 – 168 . 5. MacDonald JS Schein PS Woolley PV . 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for